Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Martell

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Kidney International|March 11, 2021
The genetic background significantly impacts the severity of kidney cystic disease in the Pkd1<sup>RC/RC</sup> mouse model of autosomal dominant polycystic kidney diseaseJennifer Arroyo, Diana Escobar-Zarate, Harrison H Wells, et al.
Bioorganic & Medicinal Chemistry Letters|November 27, 2010
Structure-activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonistsMin Zhong, Emily J Hanan, Wang Shen, et al.
Translational Psychiatry|July 5, 2025
Prediction of generalized anxiety disorder treatment outcomes with neurobehavioral responses to approach-avoidance conflict: a randomized clinical trialHannah Berg, Timothy J McDermott, Rayus Kuplicki, et al.
Journal of Mood and Anxiety Disorders|February 22, 2024
A randomized clinical trial of behavioral activation and exposure-based therapy for adults with generalized anxiety disorderHannah Berg, Elisabeth Akeman, Timothy J McDermott, et al.
Journal of Mood and Anxiety Disorders|July 14, 2025
Corrigendum to "A randomized clinical trial of behavioral activation and exposure-based therapy for adults with generalized anxiety disorder" [J. Mood Anxiety Disord., vol. 1, June 2023, 100004]Hannah Berg, Elisabeth Akeman, Timothy J McDermott, et al.
Bioorganic & Medicinal Chemistry Letters|July 27, 2010
Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonistsMin Zhong, Wang Shen, Kenneth J Barr, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Kidney International|March 11, 2021
The genetic background significantly impacts the severity of kidney cystic disease in the Pkd1<sup>RC/RC</sup> mouse model of autosomal dominant polycystic kidney diseaseJennifer Arroyo, Diana Escobar-Zarate, Harrison H Wells, et al.
Bioorganic & Medicinal Chemistry Letters|November 27, 2010
Structure-activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonistsMin Zhong, Emily J Hanan, Wang Shen, et al.
Translational Psychiatry|July 5, 2025
Prediction of generalized anxiety disorder treatment outcomes with neurobehavioral responses to approach-avoidance conflict: a randomized clinical trialHannah Berg, Timothy J McDermott, Rayus Kuplicki, et al.
Journal of Mood and Anxiety Disorders|February 22, 2024
A randomized clinical trial of behavioral activation and exposure-based therapy for adults with generalized anxiety disorderHannah Berg, Elisabeth Akeman, Timothy J McDermott, et al.
Journal of Mood and Anxiety Disorders|July 14, 2025
Corrigendum to "A randomized clinical trial of behavioral activation and exposure-based therapy for adults with generalized anxiety disorder" [J. Mood Anxiety Disord., vol. 1, June 2023, 100004]Hannah Berg, Elisabeth Akeman, Timothy J McDermott, et al.
Bioorganic & Medicinal Chemistry Letters|July 27, 2010
Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonistsMin Zhong, Wang Shen, Kenneth J Barr, et al.
Pageof 4